跳到主要內容

臺灣博碩士論文加值系統

(44.192.38.248) 您好!臺灣時間:2022/11/27 06:07
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:梁淑菁
研究生(外文):Shu-Ching Liang
論文名稱:肺癌細胞 ABCG2 蛋白分布於細胞核中並調控CDH1基因表現之研究
論文名稱(外文):ABCG2 localizes to the nucleus and modulates CDH1expression in lung cancer cells
指導教授:林奇宏林奇宏引用關係
指導教授(外文):Chi-Hung Lin
學位類別:博士
校院名稱:國立陽明大學
系所名稱:微生物及免疫學研究所
學門:生命科學學門
學類:微生物學類
論文種類:學術論文
論文出版年:2015
畢業學年度:103
語文別:英文
論文頁數:75
中文關鍵詞:肺癌ABCG2CDH1上皮細胞中胚轉化轉移
外文關鍵詞:Lung cancerABCG2CDH1EMTmetastasis
相關次數:
  • 被引用被引用:0
  • 點閱點閱:236
  • 評分評分:
  • 下載下載:3
  • 收藏至我的研究室書目清單書目收藏:0
ABCG2蛋白屬於ATP-binding cassette 運送家族成員之一,主要分佈在細胞膜上,普遍存在於各種不同的人類腫瘤細胞中,例如肺癌細胞。此基因的功能可使細胞具有多重抗藥性有關,以及可藉由篩選側邉細胞群的方式來找尋肺癌癌症幹細胞。此篇研究利用免疫螢光染色法、細胞核質分離法以及免疫組織化學染色法証實在肺癌細胞及臨床肺癌組織中,ABCG2 蛋白不僅僅表現在細胞膜上也存在於細胞
核內。進一步發現細胞核內的ABCG2 蛋白可藉由與CDH1 基因上游E-box 序列
的結合,進而調控CDH1 基因的表現。CDH1 基因可轉譯出E-cadherin 蛋白,其表現量的高低影響腫瘤細胞轉移能力。當細胞中的ABCG2 大量表達時會使
E-cadherin 表現也隨之增加,而促使細胞移動能力減緩;相反的,若降低ABCG2表達量時,E-cadherin 表現減少而導致細胞移動能力增加。此外,在小鼠動物實驗模式中利用皮下注射的方式,將ABCG2 不同表現量的肺癌細胞株A549 植入免疫不全的小鼠腹部使之形成腫瘤,發現ABCG2 低表現量的細胞有較強的轉移能力,可於肺部或大腸組織中發現有腫瘤形成。然而,若利用尾靜脈注射方式使肺癌細胞株透過血液循環至全身器官,實驗結果發現ABCG2 高表現量的肺癌細胞較易於遠端處聚落增生而形成轉移腫瘤。因此,本研究提出細胞核內ABCG2
蛋白扮演一個全新的角色,具轉錄因子調控功能影響E-cadherin 表現,進而參與癌症轉移的調控。
Breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette (ABC) transporter family. The presence of ABCG2 on the plasma membrane in many kinds of human cancer cells contributes to multidrug-resistance during chemotherapy, and it has been used as the side population marker for identifying cancer stem cells in lung cancers. We report here that, in addition to the membranous
form, ABCG2 proteins are also found inside the nucleus, where they bind to the E-box of CDH1 (E-cadherin) promoter and regulate transcription of this gene. Increased expression of ABCG2 causes an increase of E-cadherin and attenuates cell migration, whereas knockdown of ABCG2 down-regulates E-cadherin and enhances cell motility.
In mice, xenografted A549 cells that have less ABCG2 are more likely to metastasize from the subcutaneous inoculation site to the internal organs. However, for the cancer cells that have already entered the blood circulation, an increased level of ABCG2, and correspondingly increased E-cadherin, may facilitate circulating cancer cells to colonize at a distant site and form a metastatic tumor. We propose a novel role for
nuclear ABCG2 that functions as a transcription regulator and participates in modulation of cancer metastasis.
目錄
誌謝 i
中文摘要 ii
英文摘要 iii
目錄 iv
圖目錄 vii
表目錄 ix
縮寫表 x
Introduction 1
Lung cancer 1
BCRP/ABCG2 1
ABCG2 and side population/cancer stem cells 3
Epithelial–mesenchymal transition (EMT) or mesenchymal–epithelial transition (MET) 5
ABCG2 localization 6
Specific Aims 7
Significance 7
Material and Methods 9
Cells and Cell Culture 9
Immunofluorescence Staining 9
Extraction of Subcellular Fractions 10
Western Blotting 11
Immunohistochemistry 12
Wound Healing Migration Assay, Trans-Well Migration, and Invasion Assay 13
Plasmid Construction 14
Lentivirus Production and Transduction 15
Expression Microarray Analysis 15
Reverse Transcription and Quantitative Real-Time PCR Analysis (Q-RT-PCR) 16
Growth Curve of A549 Variant Cells 16
Flow Cytometry 17
Generation of the Reporter Construct and Luciferase Assay 17
Chromatin Immunoprecipitation Assay (ChIP) 18
Electrophoretic Mobility Shift Assay (EMSA) 18
Experimental Mouse Metastasis Model 19
Colony Formation Assay 20
Statistical Analysis 20
Results 21
1. Nuclear Distributions of ABCG2 Proteins 21
1.1 Nuclear localization of ABCG2 in lung cancer cells 21
1.2 Nuclear distributions of ABCG2 proteins in lung tissues and nuclear staining cells associated with clinical stage 23
2. Additional Biological Activities of ABCG2 24
2.1 ABCG2 affects the percentage of side population in A549 cells 24
2.2 ABCG2 affects cell morphology and inhibits cell migration in lung cancer cells 25
3. Expression Level of ABCG2 is Correlated with Genes Related to Cell Adhesion and Motility 27
3.1 To identify ABCG2 affects the expression of adhesion molecules, such as E-cadherin 27
3.2 ABCG2 affects other epithelial or mesenchymal molecules 29
4. ABCG2 is Involved in Transcriptional Regulation of CDH1 29
4.1 ABCG2 regulates CDH1 transcription through the CDH1 promoter 29
4.2 ABCG2 regulates CDH1 transcription by binding to E-box motif of CDH1 promoter 30
5. ABCG2 Attenuates Invasiveness, but Promotes Colonization of Circulating Cancer Cells 32
5.1 ABCG2 attenuates invasiveness in vivo and in vitro 32
5.2 ABCG2 promotes lung colonization in vivo and in vitro 33
Discussion 35
References 42
圖目錄
Figure 1. The localization of endogenous ABCG2 in A549 cells 50
Figure 2. Subcellular distribution of ABCG2 in A549 cells 51
Figure 3. Subcellular distribution of ABCG2 in A549 cells 52
Figure 4. The localization and expression of ABCG2 in CL1/TPT cells 53
Figure 5. The ABCG2 expression patterns in lung tissues and clinical survival analysis 54
Figure 6. ABCG2 affects side population (SP) percentage, cell morphology and motility in A549 cells 55
Figure 7. The flowchart shows how to identify the candidate molecules were affected by ABCG2 in microarray analysis 57
Figure 8. The ABCG2 expression levels of variant A549 stable cell lines (Vec-ctrl, ABCG2, shGFP, or shABCG2) in microarray experiments 58
Figure 9. ABCG2 affects expression of epithelial–mesenchymal transition (EMT) or mesenchymal–epithelial transition (MET) markers in A549 cells 59
Figure 10. The cytoplasmic and nuclear ABCG2 expression levels were compared among four A549 stable cell lines 60
Figure 11. ABCG2 enhances CDH1 transcription through the E-boxes of the CDH1 promoter 61
Figure 12. ABCG2 enhances CDH1 transcription by binding to the E-boxes of the CDH1 promoter 62
Figure 13. ABCG2 attenuates invasiveness in vivo and in vitro 64
Figure 14. ABCG2 promotes lung colonization in vivo and in vitro 65
Figure 15. Proposed metastasis model summarizing the role played by nuclear ABCG2 in up-regulating CDH1 transcription and trending MET progression in this study 66
Figure 16. The variant deletion clones of ABCG2 67
Figure 17. The expression of Snail and MMP9 in A549 stable cells 68
表目錄
Table 1: Clinicopathological characteristics of the 27 lung cancer patients in ABCG2 staining patterns 69
Table 2-1: The comparison between the clinical stage and ABCG2-Nuclear pattern 70
Table 2-2: The comparison between the clinical stage and the percentage of ABCG2-Nuclear staining cells 70
Table 3: Probe set was selected from top 100 positively/negatively correlated probes 71
Table 4: Selected genes (135) were enriched in 41 gene ontology terms 74
Table 5: Total 13 selected genes were involved in cell adhesion 75

Reference
[1] Siegel RL, Miller KD, Jemal A (2015). Cancer statistics, 2015. CA Cancer J Clin 65, 5-29.
[2] 衛生福利部國民健康署. 102年死因摘要 http://health99.hpa.gov.tw/Hot_News/h_NewsDetailN.aspx?TopIcNo=7001.
[3] Schinkel AH, Jonker JW (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55, 3-29.
[4] Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234.
[5] Dean M (2009). ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14, 3-9.
[6] Robey R, Polgar O, Deeken J, To K, Bates S (2007). ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26, 39-57.
[7] Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95, 15665-15670.
[8] Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58, 5337-5339.
[9] Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, et al. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59, 8-13.
[10] Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyoda Y, Koshiba S, Ishikawa T (2009). Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J 276, 7237-7252.
[11] Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B (2001). Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285, 111-117.
[12] Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH (2002). Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest 110, 659-669.
[13] Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A, Ishikawa T (2006). Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol 5, 205-222.
[14] Diestra JE, Scheffer GL, Català I, Maliepaard M, Schellens JHM, Scheper RJ, Germà-Lluch JR, Izquierdo MA (2002). Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198, 213-219.
[15] Austin Doyle L, Ross DD (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358.
[16] Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61, 3458-3464.
[17] Assaraf YG (2006). The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9, 227-246.
[18] Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183, 1797-1806.
[19] Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med 7, 1028-1034.
[20] Scharenberg CW, Harkey MA, Torok-Storb B, Scharenberg CW, Harkey MA, Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512.
[21] Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K (2002). The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8, 22-28.
[22] Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC, Jonker JW, Freeman J, et al. (2005). Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23, 1059-1065.
[23] Ding XW, Wu JH, Jiang CP (2010). ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86, 631-637.
[24] Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A 99, 12339-12344.
[25] Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279, 24218-24225.
[26] Israeli D, Ziaei S, Gonin P, Garcia L (2005). A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. J Theor Biol 232, 41-45.
[27] Susanto J, Lin YH, Chen YN, Shen CR, Yan YT, Tsai ST, Chen CH, Shen CN (2008). Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS One 3, e4023.
[28] Bhattacharya S, Das A, Mallya K, Ahmad I (2007). Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci 120, 2652-2662.
[29] Apati A, Orban TI, Varga N, Nemeth A, Schamberger A, Krizsik V, Erdelyi-Belle B, Homolya L, Varady G, Padanyi R, et al. (2008). High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim Biophys Acta 1778, 2700-2709.
[30] Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
[31] Visvader JE, Lindeman GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755-768.
[32] Hermann PC, Bhaskar S, Cioffi M, Heeschen C (2010). Cancer stem cells in solid tumors. Semin Cancer Biol 20, 77-84.
[33] Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-513.
[34] Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, Reisfeld RA, Kruger JA, Kaplan CD, Luo Y, et al. (2006). Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108, 3906-3912.
[35] Ho MM, Ng AV, Lam S, Hung JY (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67, 4827-4833.
[36] Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, Wang J, Han X, Shi Y, Lu SH (2009). Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18, 465-473.
[37] Zhang P, Zhang Y, Mao L, Zhang Z, Chen W (2009). Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 277, 227-234.
[38] Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F (2005). Cancer stem cell characteristics in retinoblastoma. Mol Vis 11, 729-737.
[39] Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, et al. (2008). Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134, 1155-1163.
[40] Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ, Xu XX (2009). A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56, 371-378.
[41] Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N (2011). Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 35, 227-234.
[42] Li F, Zeng H, Ying K (2011). The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28, 1458-1462.
[43] Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004). Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10, 1691-1697.
[44] Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, et al. (2009). Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64, 98-104.
[45] Thiery JP, Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142.
[46] Shih JY, Yang PC (2011). The EMT regulator slug and lung carcinogenesis. Carcinogenesis 32, 1299-1304.
[47] Solazzo M, Fantappie O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R (2009). Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69, 7235-7242.
[48] Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ (2008). Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 123, 1712-1720.
[49] Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM, Chen JS, et al. (2006). EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116, 401-406.
[50] Yeboah D, Kalabis GM, Sun M, Ou RC, Matthews SG, Gibb W (2008). Expression and localisation of breast cancer resistance protein (BCRP) in human fetal membranes and decidua and the influence of labour at term. Reprod Fertil Dev 20, 328-334.
[51] Bhatia P, Bernier M, Sanghvi M, Moaddel R, Schwarting R, Ramamoorthy A, Wainer IW (2012). Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica 42, 748-755.
[52] Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, et al. (2011). Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 286, 20558-20568.
[53] Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005). Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65, 6943-6949.
[54] Tsai YT, Lin CI, Chen HK, Lee KM, Hsu CY, Yang SJ, Yeh NH (2008). Chromatin tethering effects of hNopp140 are involved in the spatial organization of nucleolus and the rRNA gene transcription. J Biol Sci 15, 471-486.
[55] Tsai YH, Wu MF, Wu YH, Chang SJ, Lin SF, Sharp TV, Wang HW (2009). The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. J Virol 83, 622-632.
[56] Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1, 417-425.
[57] Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al. (2010). Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12, 982-992.
[58] Yang CY, Kuo TH, Ting LP (2006). Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response. J Biol Chem 281, 34525-34536.
[59] Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, R60.1-60.11.
[60] Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, et al. (2008). The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283, 3349-3356.
[61] Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K (2003). Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278, 39068-39075.
[62] Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC, Bleau A-M, Hambardzumyan D, Ozawa T, et al. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
[63] Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP, Zeng H (2013). Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 336, 96-105.
[64] Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM (1995). Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68, 226-239.
[65] Hennig G, Löwrick O, Birchmeier W, Behrens J (1996). Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem 271, 595-602.
[66] Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD (2000). E-cadherin Is a WT1 Target Gene. J Biol Chem 275, 10943-10953.
[67] Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000). The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83.
[68] Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia de Herreros A (2000). The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84-89.
[69] Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F (2001). The two-handed E Box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7, 1267-1278.
[70] Hajra KM, Chen DY-S, Fearon ER (2002). The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62, 1613-1618.
[71] Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
[72] Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D, Birchmeier W (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113, 173-185.
[73] Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP (2011). Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 22, 2423-2435.
[74] Chao Y, Shepard C, Wells A (2010). Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9, 1-18.
[75] Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED (2006). Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66, 11271-11278.
[76] Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J (2009). miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4, e7181.
[77] Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, Chen Y, Zhang T, Wang X, et al. (2012). PI3K/Akt to GSK3β/β-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cell Signal 24, 2273-2282.
[78] Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, Massagué J, Benezra R (2013). TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 5, 1228-1242.
[79] Seo DC, Sung JM, Cho HJ, Yi H, Seo KH, Choi IS, Kim DK, Kim JS, El-Aty AA, Shin HC (2007). Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 6, 75.
[80] Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, et al. (2011). Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Med 17, 1101-1108.
[81] Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, et al. (2012). Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 122, 1849-1868.
[82] Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA (2012). Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724.
[83] Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736.
[84] Li R, Liang J, Ni S, Zhou T, Qing X, Li H, He W, Chen J, Li F, Zhuang Q, et al. (2010). A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 7, 51-63.
[85] Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, Woltjen K, Nagy A, Wrana JL (2010). Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7, 64-77.
[86] Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, Chen ST, Tai SK, Kuo ML, Yang MH (2013). Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res 73, 4147-4157.
[87] Gong W, Wang Z, Wan Y, Shi L, Zhou Y (2014). Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells. Neuroreport 25, 625-632.
[88] Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X (2014). miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med 16, 517-528.



連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊